Posts Tagged ‘Type 2 diabetes’

Diabetes Rates Soar

November 28th, 2012

The Center for Disease Control and Prevention (CDC) has reported that the prevalence of diagnosed diabetes has increased in all US states, the District of Columbia and Puerto Rico between 1995 and 2010. The prevalence increased by 50% or more in 42 states and by 100% or more in 18 states. The states with the largest increases were Oklahoma, Kentucky, Georgia, Alabama and Washington. According to the CDC press release, in 1995 only 3 states had diagnosed diabetes prevalence of 6% or more; by 2010, all 50 states had a prevalence over 6%.

The press release, (rather amazingly to my point of view) states, “Type 2 diabetes, which may be prevented through lifestyle changes, accounts for 90 percent to 95 percent of all diabetes cases in the United States. CDC and its partners are working on a variety of initiatives to prevent type 2 diabetes and to reduce complications in those already diagnosed. CDC leads the National Diabetes Prevention Program, a public-private partnership that brings evidence-based programs for preventing type 2 diabetes to communities. The program is helping to establish a network of lifestyle-change classes for overweight or obese people at high risk of developing type 2 diabetes.” Of course the evidence-based program they refer to are the Diabetes Prevention Program, which found lifestyle prevention was only effective in young retirees and the Look AHEAD trial, which was terminated prematurely because the lifestyle group had no better outcomes than the control group. Why does the CDC continue to hype bang-the- lifestyle-drum when they know it doesn’t work?

 

Type 2 Diabetes Harder to Treat in Children

May 1st, 2012

An article by Denise Grady in the New York Times reports on a study that type 2 diabetes in children is harder to treat and more virulent that in adults. The article recounts story of Sara Chernov who learned she had type 2 diabetes when she was 16. “ Her grandfather had had both legs amputated as a result of the disease and one of the first questions she asked was when she would lose her legs and her eyesight. A doctor scolded her for being fat and told her she had to lose weight and could never eat sugar again. She left the office in tears and did not go back.” NYT: Obesity type 2 diabetes worse in children See the article at NEJM: Clinical Trial Glycemic Control in Youth

This is one of those “really bad news” papers. Patients were 10 to 17 years old and treated with metformin to reach a HbA1c level below 8% They were randomized to metformin alone or metformin with rosiglitazone or lifestyle-intervention focusing on weight loss through eating and activity behaviors. Of the 699 participants, only 45.6% reached the primary outcome over an average of 3.86 years of follow-up. Rates of failure were 51% for metformin alone, 38.6% for metformin plus rosiglitazone and 46.6% for metformin plus lifestyle. Metformin alone was least effective in non-Hispanic black participants and metformin plus rosiglitazone was most effective in girls.

Serious adverse events were reported in 19.2% of participants; including 18.1% in the metformin group, 14.6% in the metformin-rosiglitazone group and 24.8% in the metformin plus lifestyle group.

Differences in outcomes were not attributable to adherence or changes in BMI.

 

How Blame Gets in the Way

February 5th, 2012

Recommended reading. Sara Sklaroff has written an eloquent essay on what it means to live with type 2 diabetes. On Our Own: Why We Who Struggle To Live With Diabetes Could Use A Helping Hand

FDA Approves Once Weekly Drug for Diabetes; Shows Weight Loss

January 28th, 2012

The Food and Drug Administration has approved Amylin Pharmaceutical’s Bydureon for thetreatment of type 2 diabetes. This is the first once-weekly treatment for type 2 diabetes. It is hoped that this feature will lead to higher adherence to the treatment regimen, although as with Byetta, it is injectable. The drug is exenatide, a GLP-1 receptor agonist. Study results showed an improvement in glycemic control.  A1C levels, a measure of blood sugar, decreased an average of 1.6 points.

Many patients with Type 2 diabetes are also overweight or obese. Many drugs for type 2 diabetes actually cause weight gain. The advantage of Bydureon (and its daily administered counterpart, Byetta) is that patients taking Bydureon can achieve weight loss, in addition to improvements in glycemia, blood pressure, and cholesterol in both overweight and obesity subjects with and without type 2 diabetes. Effects of glucagon-like peptide-1 receptor agonists on … [BMJ. 2012] – PubMed – NCBI

A very small study of 12 children and adolescents with extreme obesity also showed significant improvements, suggesting the need for a larger study. Exenatide as a weight-loss therapy i… [Obesity (Silver Spring). 2012] – PubMed – NCBI

More information is available at www.BYDUREON.com.

NIH Recommends A1c Testing

January 26th, 2012

The National Institutes of Health has come out for expanded A1c testing. Their press release and fact sheet point out that the A1c test does not require fasting and helps identify diabetes and pre-diabetes. They recommend testing of anyone 45 years old or younger than 45 are overweight, inactive or have at least one risk factor for type 2 diabetes. New NIH fact sheet explains test for diabetes, prediabetes, January 26, 2012 News Release – National Institutes of Health (NIH)

NIH Disses Physical Activity as Cure of Childhood Obesity

November 23rd, 2011

The National Heart, Lung and Blood Institute has issued guidelines endorsed by the American Academy of Pediatrics. They are directed to all primary pediatric care providers to address the known risk factors of cardiovascular disease, including obesity, blood pressure, cholesterol, tobacco and lipids.

The report notes that longitudinal data on non-white populations are lacking and that “Clinically important differences in prevalence of risk factors exist according to race and gender, particularly with regard to tobacco-use rates, obesity prevalence, hypertension, and dyslipidemia.”

The report notes, “Obesity tracks more strongly than any other risk factor, among many reports from studies that have demonstrated this fact…Tracking data on physical data is more limited.”

Regarding overweight and obesity, the report states,

“The dramatic increases in childhood overweight and obesity in the United States since 1980 are an important public health focus. Despite efforts over the last decade to prevent and control obesity, recent reports from the National Health and Nutrition Examination Survey show sustained high prevalence: 17% of children and adolescents have a BMI at the >95th percentile for age and gender. The presence of obesity in childhood in childhood and adolescence is associated with increased evidence of atherosclerosis at autopsy and of subclinical measures of atherosclerosis on vascular imaging. Because of its strong association with many of the other established risk factors for cardiovascular disease, obesity is even more powerfully correlated with atherosclerosis; this association has been shown for BP, dyslipidemia, and insulin resistance in each of the major pediatric epidemiologic studies. Of all of the risk factors, obesity tracks most strongly from childhood into adult life.”

Given that physical activity is a primary prescription for preventing childhood and adolescent obesity, it is interesting to read what the expert panel has to say about its utility:

“A moderate number of RCTs (randomized controlled clinical trials) have evaluated the effect of interventions that addressed only physical activity and/or sedentary behavior on prevention of overweight and obesity. In a small number of these studies, the intervention was effective. It should be noted that these successful interventions often addressed reduction in sedentary behavior rather than attempts to increase physical activity. In a majority of these studies there was no significant difference in body-size measures. Sample sizes were often small and follow-up was often short (frequently < 6 months). ..Overall, the expert panel concluded that on the basis of the evidence review, increasing activity in isolation is of little benefit in preventing obesity. By contrast, the review suggests that reducing sedentary behavior might be beneficial in preventing the development of obesity.”

The report identifies populations at special risk for obesity: children with a BMI between the 85 and 95th percentiles;children in whom there is a positive family history of obesity in 1 or both parents; early onset of increasing weight; excessive weight gain during adolescence; children who have been very active and become inactive. See Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents- NHLBI, NIH

Staggering New Cost Projections for Obesity

November 22nd, 2011

Simulation model predicts increased health care costs and utilization in rising obese populations in the United States and the United Kingdom, predicting 65 million more obese in the US and 11 million more in the UK, meaning 6 to 8.5 million cases of diabetes, 5.7 to 7.3 million cases of heart disease, 492,000 to 669,000 additional cases of cancer in the US and UK combined. The combined health care costs increases are $48-66 billion per year in the US and by £1·9-2  billion  per year in the United Kingdom. Health and economic burden of the projected obesity t… [Lancet. 2011] – PubMed – NCBI

Effects of Childhood Obesity Can be Reversed

November 17th, 2011

An analysis (published today in the New England Journal of Medicine) of over 6,000 subjects followed for 23 years found persons who were obese in childhood had high risk of type 2 diabetes, hypertension, elevated low-density and high-density cholesterol, triglyceride levels as well as carotid-artery atherosclerosis compared to persons who were never obese. However, persons who were obese as children but normal weight as adults had risk similar to those with a normal BMI consistently from childhood to adulthood. The New England Journal of Medicine: Research & Review Articles on Disease & Clinical Practice